Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Popular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Get personalized support, product recommendations, video calls, and more from our researchers, trichologists, and PhD's dedicated to getting you the best possible outcomes.
Learn MoreCan your genes predict the effectiveness of PGD2 inhibitors for hair loss? The GPR44 gene, encoding the prostaglandin D2 receptor (DP2), is a potential target in hair loss treatment. Elevated levels of prostaglandin D2 (PGD2) have been linked to hair growth inhibition, making GPR44 a key player. However, while early studies showed promise, follow-up research yielded mixed results, and a clinical trial of a GPR44 blocker did not show significant efficacy. This article explores the role of GPR44 in hair loss, the current state of research, and whether genetic variations in GPR44 can influence treatment response.
GPR44 is a gene that encodes the G-protein-coupled receptor 44, also known as the prostaglandin D2 receptor (DP2). This receptor plays a pivotal role in various physiological processes, including inflammation and immune responses.
GPR44 is considered significant in the context of hair loss because some believe it is involved in hair growth inhibition.
Early studies evaluating prostaglandin activity in the hair follicle found that elevated levels of prostaglandin D2 (PGD2) have been found in the scalps of individuals with androgenic alopecia. PGD2 exerts its effects through the GPR44 receptor.
This article will delve into the importance of the GPR44 gene in hair loss, its potential as a therapeutic target, and the significant role that understanding your genetic makeup can play in making informed treatment decisions.
The GPR44 gene (also called CRTh2) codes for the expression of a type of receptor for prostaglandins, specifically PGD2.[1]National Library of Medicine. (2024). PTGDR2 Prostaglandin D2 Receptor 2 [Homo sapiens (human)]. NIH. Available at: https://www.ncbi.nlm.nih.gov/gene/11251 (Accessed: 12 July 2024.) Prostaglandin D2 is a bioactive lipid compound that belongs to the family of prostaglandins, which are derived from arachidonic acid. Prostaglandins are involved in various physiological processes, including inflammation, allergic reactions, and regulation of sleep-wake cycles. PGD2 is produced by several types of cells, including mast cells, dendritic cells, and other types of immune cells.
Studies suggest that PGD2 has been found to inhibit hair growth in isolated human hair follicles and mice. Furthermore, PGD2 has been found to be elevated in the scalps of balding men diagnosed with androgenetic alopecia.[2]Nieves, A., Garza, L.A. (2014). Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness? Experimental Dermatology. 23(4). 224-227. Available at: https://doi.org/10.1111/exd.12348[3]Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). … Continue reading
As mentioned above, PGD2 binds to its receptor, GPR44, to exert its effects. Studies on human scalp samples from the bald and haired areas of balding men found that the level of PGD2 was significantly higher in the scalps of the balding areas (Figure 1). Furthermore, PGE2, which has been linked to human hair growth, was found to be significantly lower in the bald scalp (Figure 1).[4]Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). … Continue reading
The same study evaluated the effect of high levels of PGD2 in mouse skin, hypothesizing that it might lead to the initiation of features of androgenic alopecia. The researchers used K14-Ptgs2 transgenic mice that are genetically modified to overexpress the Ptgs2 gene (also known as COX-2) specifically in the skin. These mice are often used in prostaglandin signaling studies as these specific genetic modifications increase levels of PGD2, PGE2, and 15-dPGJ2.
The mice overexpressing this gene were found to have hair follicles that entered premature catagen with subsequent development of alopecia.[6]Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). … Continue reading
In a series of experiments, researchers investigated the effects of prostaglandin D2 (PGD2) on hair growth using C57Bl/6 mice, a common laboratory strain. They topically applied PGD2 to the shaved backs of these mice and measured hair length 20 days after depilation.
The results showed a significant inhibition of hair growth in the treated areas. To further explore the mechanism, the team used a separate mouse model with the GPR44 gene (which encodes a PGD2 receptor) knocked out. Interestingly, these GPR44-deficient mice demonstrated resistance to hair loss when PGD2 was applied topically, indicating that PGD2’s effect on hair loss was through the GPR44 receptor.[7]Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). … Continue reading
Clinical studies have found an association between the rs533116 and rs545659 polymorphisms of the GPR44 gene that enhances the expression of GPR44 in the lungs, resulting in an increase in asthma severity.[9]Campos Alberto, E., Maclean, E., Davidson, C., Palikhe, N.S., Storie, J., Tse, C., Brenner, D., Mayers, I., Vliagoftis, H., El-Sohemy, A., Cameron, L. (2012). The Single Nucleotide Polymorphism CRTh2 … Continue reading[10]Huang, J.L., Gao, P.S., Mathias, R.A., Yao, T.C., Chen, L.C., Kuo, M.L., Hsu, S.C., Plunkett, B., Togias, A., Barnes, K.C., Stellato, C., Beaty, T.H., Huang, S.K. Sequence Variants of the Gene … Continue reading
This increase in the expression of receptors like GPR44 may increase responsiveness to PGD2, so it’s possible that these findings may also apply to people with androgenic alopecia.
In 2012, a study from the University of Pennsylvania and Johns Hopkins University generated a lot of excitement about a potential new treatment avenue for hair loss. The researchers found that PGD2 was elevated in the balding scalp but not in non-balding areas of the scalp of men with hair loss. Furthermore, they found that PGD2 inhibits hair growth.[11]Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). … Continue reading. This sparked an interest in prostaglandins as hair growth inhibitors.
Unfortunately, follow-up studies showed conflicting results – thanks to poorly controlled variables – and it is still unclear whether there is a causal relationship between prostaglandins and androgenetic alopecia.[12]English, R., Ruiz, S. (2021). Conflicting Reports Regarding the Histopathological Features of Androgenic Alopecia: Are Biopsy Location, Hair Diameter Diversity, and Relative Hair Follicle … Continue reading
A randomized, double-blind, placebo-controlled Phase 2a trial on setipiprant, a drug designed to bind to GPR44 and block PGD2 from exerting its effect, was conducted on males aged 18-49 with androgenic alopecia. The study found that setipiprant at 1000 mg twice daily for 24 weeks did not demonstrate efficacy compared to a placebo in improving hair growth, as measured by target area hair count and participant self-assessment. While setipiprant was safe and well-tolerated, it failed to show significant improvements indicating that targeting PGD2 alone is not sufficient to treat male pattern hair loss.[13]DuBois, J., Bruce, S., Stewart, D., Kempers, S., Harutunian, C., Boodhoo, T., Weitzenfeld, A, Chang-Lin, J.E. (2021). Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, … Continue reading
Your Result | GPR44-1 Variant 1 | GPR44-2 Variant 2 | |
Rs545659 TT | Rs545659 AA | ||
What it means | May be at a lower risk of having elevated levels of PGD2 in the lungs/scalp. | May be at an increased risk of having higher levels of GPR44 in the lungs/scalp. | |
The Implication | You might not be a good candidate for PGD2 inhibitors as a treatment for hair loss | You might be a better candidate for PGD2 inhibitors as a treatment for hair loss | |
Your Result | GPR44-1 Variant 1 | GPR44-2 Variant 2 | GPR44-2 Variant 3 |
Rs533116 AA | Rs533116 GG | Rs533116 GA | |
What it means | May be at a lower risk of having elevated levels of PGD2 In the lungs/scalp. | May be at moderate risk of having higher levels of GPR44 in the lungs/scalp. | May be at an increased risk of having higher levels of GPR44 in the lungs/scalp. |
The Implication | You might not be a good candidate for PGD2 inhibitors as a treatment for hair loss | You might be an average candidate for PGD2 inhibitors as a treatment for hair loss | You might be a better candidate for PGD2 inhibitors as a treatment for hair loss |
We have also created a rubric that helps to determine the relevance of a specific gene to hair loss based on the quality of the evidence in the above studies.
Yes, initial studies have shown that PGD2 levels are increased in the scalps of balding men. Experiments in mice suggest that PGD2 may inhibit hair growth. (score = 1)
There is not enough consistency of evidence to support the relationship between prostaglandin activity and androgenetic alopecia, due to further results conflicting with initial results. (score = 0)
Although earlier studies showed that PGD2 is elevated in balding scalps, targeting this has not shown to be effective at treating hair loss. (score = 0)
No score on number (3). (score = 0)
Total Score = 1
While early research has highlighted the potential involvement of the GPR44 gene in hair loss through its interaction with prostaglandin D2 (PGD2), the current evidence is not robust enough to make definitive treatment recommendations based solely on the GPR44 genotype. Therefore, more comprehensive and consistent research is needed to validate the role of GPR44 in hair loss and its potential as a predictive factor for treatment responsiveness.
References[+]
↑1 | National Library of Medicine. (2024). PTGDR2 Prostaglandin D2 Receptor 2 [Homo sapiens (human)]. NIH. Available at: https://www.ncbi.nlm.nih.gov/gene/11251 (Accessed: 12 July 2024.) |
---|---|
↑2 | Nieves, A., Garza, L.A. (2014). Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness? Experimental Dermatology. 23(4). 224-227. Available at: https://doi.org/10.1111/exd.12348 |
↑3, ↑4, ↑6, ↑7 | Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). Prostaglandin D2 Inhibits Hair Growth and is Elevated in Bald Scalp of Men with Androgenetic Alopecia. Science Translational Medicine. 4(126). 1-21. Available at: https://doi.org/10.1126/scitranslmed.3003122 |
↑5, ↑8, ↑11 | Garza, L.A., Liu, Y., Alagesan, B., Lawson, J.A., Norberg, S.M., Loy, D.R., Zhao, T., Blatt, H.B., Stanton, D.C., Carrasco, L., Ahluwalia, G., Fischer, S.M., Fitzgerald, G.A., Cotsarelis, G. (2012). Prostaglandin D2 Inhibits Hair Growth and is Elevated in Bald Scalp of Men with Androgenetic Alopecia. Science Translational Medicine. 4(126). 1-21. Available at: https://doi.org/10.1126/scitranslmed.3003122 |
↑9 | Campos Alberto, E., Maclean, E., Davidson, C., Palikhe, N.S., Storie, J., Tse, C., Brenner, D., Mayers, I., Vliagoftis, H., El-Sohemy, A., Cameron, L. (2012). The Single Nucleotide Polymorphism CRTh2 rs533116 is Associated with Allergic Asthma and Increased Expression of CRTh2. Allergy. 67(11). 1357-1364. Available at: https://doi.org/10.1111/all.12003 |
↑10 | Huang, J.L., Gao, P.S., Mathias, R.A., Yao, T.C., Chen, L.C., Kuo, M.L., Hsu, S.C., Plunkett, B., Togias, A., Barnes, K.C., Stellato, C., Beaty, T.H., Huang, S.K. Sequence Variants of the Gene Encoding Chemoattractant Receptor Expressed on Th2 Cells (CRTH2) are Associated with Asthma and Differentially Influence mRNA Stability. Human Molecular Genetics. 13(21). 2691-2697. Available at: https://doi.org/10.1093/hmg/ddh279 |
↑12 | English, R., Ruiz, S. (2021). Conflicting Reports Regarding the Histopathological Features of Androgenic Alopecia: Are Biopsy Location, Hair Diameter Diversity, and Relative Hair Follicle Miniaturization Partly to Blame? Clinical, Cosmetic, and Investigational Dermatology. 14. 357-365. Available at: https://doi.org/10.2147/CCID.S306157 |
↑13 | DuBois, J., Bruce, S., Stewart, D., Kempers, S., Harutunian, C., Boodhoo, T., Weitzenfeld, A, Chang-Lin, J.E. (2021). Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial. Clinical Cosmetic and Investigative Dermatology. 14. 1507-1517. Available at: https://doi.org/10.2147/CCID.S319676 |
Get personalized support, product recommendations, video calls, and more from our researchers, trichologists, and PhD's dedicated to getting you the best possible outcomes.
Learn MoreDr. Sarah King is a researcher & writer who holds a BSc in Medical Biology, an MSc in Forensic Biology, and a Ph.D. in Molecular and Cellular Biology. While at university, Dr. King’s research focused on cellular aging and senescence through NAD-dependent signaling – along with research into prostaglandins and their role in hair loss. She is a co-author on several upcoming manuscripts with the Perfect Hair Health team.
Get personalized support, product recommendations, video calls, and more from our researchers, trichologists, and PhD's dedicated to getting you the best possible outcomes.
Join Now